newsfilter
← Latest News
Business Wire·

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion o